2 results
Approved WMOCompleted
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
Approved WMOCompleted
Primary Objective: a reduction in bronchoconstriction, measured by auto-PEEP, in patients with AE-COPD. Secondary Objective(s): * To test for a dose-dependency. * Decrease in pulmonary artery pressures* Enhance cardiac output* Measure occurrence of…